nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

Therapeutic Antibody Engineering and Selection Strategies

verfasst von : Joana Ministro, Ana Margarida Manuel, Joao Goncalves

Erschienen in: Current Applications of Pharmaceutical Biotechnology

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Antibody drugs became an increasingly important element of the therapeutic landscape. Their accomplishment has been driven by many unique properties, in particular by their very high specificity and selectivity, in contrast to the off-target liabilities of small molecules (SMs). Antibodies can bring additional functionality to the table with their ability to interact with the immune system, and this can be further manipulated with advances in antibody engineering.

The expansion of strategies related to discovery technologies of monoclonal antibodies (mAbs) (phage display, yeast display, ribosome display, bacterial display, mammalian cell surface display, mRNA display, DNA display, transgenic animal, and human B cell derived) opened perspectives for the screening and the selection of therapeutic antibodies for, theoretically, any target from any kind of organism. Moreover, antibody engineering technologies were developed and explored to obtain chosen characteristics of selected leading candidates such as high affinity, low immunogenicity, improved functionality, improved protein production, improved stability, and others. This chapter contains an overview of discovery technologies, mainly display methods and antibody humanization methods for the selection of therapeutic humanized and human mAbs that appeared along the development of these technologies and thereafter. The increasing applications of these technologies will be highlighted in the antibody engineering area (affinity maturation, guided selection to obtain human antibodies) giving promising perspectives for the development of future therapeutics.

Graphical Abstract

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Insights on the Formulation of Recombinant Proteins

Nächstes Kapitel Cytokines and Growth Factors

Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18:21–25. https://doi.org/10.1080/08998280.2005.11928028CrossRef

von Behring E, Kitasato S (1991) The mechanism of diphtheria immunity and tetanus immunity in animals. Mol Immunol 28:1317, 1319–1320

Davies DR, Chacko S (1993) Antibody structure. Acc Chem Res 26:421–427. https://doi.org/10.1021/ar00032a005CrossRef

Pauling L (1940) A theory of the structure and process of formation of antibodies. J Am Chem Soc 62:2643–2657. https://doi.org/10.1021/ja01867a018CrossRef

Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497CrossRef

Hooks MA, Wade CS, Millikan WJ (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26–37

Singh S, Kumar NK, Dwiwedi P et al (2018) Monoclonal antibodies: a review. Curr Clin Pharmacol 13:85–99. https://doi.org/10.2174/1574884712666170809124728CrossRef

Strohl WR (2017) Analysis of the current antibody landscape. In: Antibody engineering and therapeutics. San Diego

Goldsby RA, Kindt TJ, Osborne BA, Kuby J (2003) Immunology, 5th edn. W. H. Freeman, New York

10.

Poljak RJ, Amzel LM, Avey HP et al (1973) Three-dimensional structure of the Fab’ fragment of a human immunoglobulin at 2.8-A resolution. Proc Natl Acad Sci 70:3305–3310. https://doi.org/10.1073/pnas.70.12.3305CrossRef

11.

Inbar D, Hochman J, Givol D (1972) Localization of antibody-combining sites within the variable portions of heavy and light chains. Proc Natl Acad Sci 69:2659–2662. https://doi.org/10.1073/pnas.69.9.2659CrossRef

12.

Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640–656. https://doi.org/10.1016/j.addr.2006.01.026CrossRef

13.

García Merino A (2011) Monoclonal antibodies. Basic features. Neurologia 26:301–306. https://doi.org/10.1016/j.nrl.2010.10.005CrossRef

14.

Cruse JM, Lewis R (2010) Atlas of immunology, 3rd edn. CRC Press, Boca Raton

15.

Male D, Brostoff J, Roth D, Roitt I (2006) Immunology, 7th edn. Elsevier, Philadelphia

16.

Vandyk L, Meek K (1992) Assembly of IgH CDR3: mechanism, regulation, and influence on antibody diversity. Int Rev Immunol 8:123–133. https://doi.org/10.3109/08830189209055568CrossRef

17.

Morea V, Lesk AM, Tramontano A (2000) Antibody modeling: implications for engineering and design. Methods 20:267–279. https://doi.org/10.1006/meth.1999.0921CrossRef

18.

Padlan EA, Abergel C, Tipper JP (1995) Identification of specificity-determining residues in antibodies. FASEB J 9:133–139. https://doi.org/10.1096/fasebj.9.1.7821752CrossRef

19.

Mandigan M, Martinko J (2006) Brock biology of microorganisms, 11th edn. Pearson Prentice Hall, Upper Saddle River

20.

O’Kennedy R, Fitzgerald S, Murphy C (2017) Don’t blame it all on antibodies – the need for exhaustive characterisation, appropriate handling, and addressing the issues that affect specificity. TrAC Trends Anal Chem 89:53–59. https://doi.org/10.1016/j.trac.2017.01.009CrossRef

21.

Murphy K (2012) Janeway’s immunobiology, 8th edn. Garland Science, New York

22.

Hozumi N, Tonegawa S (1976) Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci 73:3628–3632. https://doi.org/10.1073/pnas.73.10.3628CrossRef

23.

Goodnow CC, Basten A (1989) Self-tolerance in B lymphocytes. Semin Immunol 1:125–135

24.

Janeway C, Travers JP, Walport M, Shlomchik M (2001) Immunobiology: the immune system in health and disease, 5th edn. Garland Science, New York

25.

Chan TD, Gatto D, Wood K et al (2009) Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. J Immunol 183:3139–3149. https://doi.org/10.4049/jimmunol.0901690CrossRef

26.

Parra D, Takizawa F, Sunyer JO (2013) Evolution of B cell immunity. Annu Rev Anim Biosci 1:65–97. https://doi.org/10.1146/annurev-animal-031412-103651CrossRefPubMedCentral

27.

Goodnow CC, Vinuesa CG, Randall KL et al (2010) Control systems and decision making for antibody production. Nat Immunol 11:681–688. https://doi.org/10.1038/ni.1900CrossRef

28.

Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575–581. https://doi.org/10.1038/302575a0CrossRef

29.

Oettinger M, Schatz D, Gorka C, Baltimore D (1990) RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 248:1517–1523. https://doi.org/10.1126/science.2360047CrossRef

30.

Bassing CH, Alt FW, Hughes MM et al (2000) Recombination signal sequences restrict chromosomal V(D)J recombination beyond the 12/23 rule. Nature 405:583–586. https://doi.org/10.1038/35014635CrossRef

31.

Mansilla-Soto J, Cortes P (2003) VDJ recombination: artemis and its in vivo role in hairpin opening. J Exp Med 197:543–547. https://doi.org/10.1084/jem.20022210CrossRefPubMedCentral

32.

Mak TW, Saunders ME (2006) The immunoglobulin genes. In: The immune response. Elsevier, Amsterdam, pp 179–208

33.

Motea EA, Berdis AJ (2010) Terminal deoxynucleotidyl transferase: the story of a misguided DNA polymerase. Biochim Biophys Acta – Proteins Proteomics 1804:1151–1166. https://doi.org/10.1016/j.bbapap.2009.06.030CrossRef

34.

Malu S, Malshetty V, Francis D, Cortes P (2012) Role of non-homologous end joining in V(D)J recombination. Immunol Res 54:233–246. https://doi.org/10.1007/s12026-012-8329-zCrossRef

35.

Helmink BA, Sleckman BP (2012) The response to and repair of RAG-mediated DNA double-strand breaks. Annu Rev Immunol 30:175–202. https://doi.org/10.1146/annurev-immunol-030409-101320CrossRefPubMedCentral

36.

Chu H (2013) VDJ recombination. Cell 94:411–414. https://doi.org/10.1016/S0092-8674(00)81580-9CrossRef

37.

Elgert KD (2009) Immunology: understanding the immune system, 2nd edn. Wiley-Blacwell, New Jersey

38.

Song H, Nie X, Basu S, Cerny J (1998) Antibody feedback and somatic mutation in B cells: regulation of mutation by immune complexes with IgG antibody. Immunol Rev 162:211–218. https://doi.org/10.1111/j.1600-065X.1998.tb01443.xCrossRef

39.

Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76:1–22. https://doi.org/10.1146/annurev.biochem.76.061705.090740CrossRef

40.

Rajewsky K, Forster I, Cumano A (1987) Evolutionary and somatic selection of the antibody repertoire in the mouse. Science 238:1088–1094. https://doi.org/10.1126/science.3317826CrossRef

41.

Manis JP, Tian M, Alt FW (2002) Mechanism and control of class-switch recombination. Trends Immunol 23:31–39. https://doi.org/10.1016/S1471-4906(01)02111-1CrossRef

42.

Stavnezer J, Amemiya CT (2004) Evolution of isotype switching. Semin Immunol 16:257–275. https://doi.org/10.1016/j.smim.2004.08.005CrossRef

43.

De Silva NS, Klein U (2015) Dynamics of B cells in germinal centres. Nat Rev Immunol 15:137–148. https://doi.org/10.1038/nri3804CrossRefPubMedCentral

44.

Muramatsu M, Kinoshita K, Fagarasan S et al (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–563. https://doi.org/10.1016/S0092-8674(00)00078-7CrossRef

45.

Larson ED, Maizels N (2004) Transcription-coupled mutagenesis by the DNA deaminase AID. Genome Biol 5:211. https://doi.org/10.1186/gb-2004-5-3-211CrossRefPubMedCentral

46.

Pham P, Bransteitter R, Petruska J, Goodman MF (2003) Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424:103–107. https://doi.org/10.1038/nature01760CrossRef

47.

Lin GG, Scott JG (2012) Germinal center organization and cellular dynamics. Immunity 100:130–134. https://doi.org/10.1016/j.pestbp.2011.02.012.InvestigationsCrossRef

48.

Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F (2005) Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J 46:258–268. https://doi.org/10.1093/ilar.46.3.258CrossRef

49.

Payne WJ, Marshall DL, Shockley RK, Martin WJ (1988) Clinical laboratory applications of monoclonal antibodies. Clin Microbiol Rev 1:313–329. https://doi.org/10.1128/cmr.1.3.313CrossRefPubMedCentral

50.

Barbet J, Bardiès M, Bourgeois M et al (2012) In: Chames P (ed) Radiolabeled antibodies for cancer imaging and therapy BT – antibody engineering: methods and protocols, 2nd edn. Humana Press, Totowa, pp 681–697

51.

Breedveld FC (2000) Therapeutic monoclonal antibodies. Lancet 355:735–740. https://doi.org/10.1016/S0140-6736(00)01034-5CrossRef

52.

Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157:220–233. https://doi.org/10.1111/j.1476-5381.2009.00190.xCrossRefPubMedCentral

53.

Winter G, Milstein C (1991) Man-made antibodies. Nature 349:293–299. https://doi.org/10.1038/349293a0CrossRef

54.

Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15:42–52CrossRef

55.

Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619–1633

56.

Pavlou AK, Belsey MJ (2005) The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 59:389–396. https://doi.org/10.1016/j.ejpb.2004.11.007CrossRef

57.

Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9:S7. https://doi.org/10.1186/ar2171CrossRefPubMedCentral

58.

Teeling JL, French RR, Cragg MS et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793–1800. https://doi.org/10.1182/blood-2004-01-0039CrossRef

59.

Murphy AJ, Macdonald LE, Stevens S et al (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci 111:5153–5158. https://doi.org/10.1073/pnas.1324022111CrossRef

60.

Kennedy PJ, Oliveira C, Granja PL, Sarmento B (2017) Antibodies and associates: partners in targeted drug delivery. Pharmacol Ther 177:129–145. https://doi.org/10.1016/j.pharmthera.2017.03.004CrossRef

61.

Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126–1136. https://doi.org/10.1038/nbt1142CrossRef

62.

Weir ANC, Nesbitt A, Chapman AP et al (2002) Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc Trans 30:512–516CrossRef

63.

Fischer N, Léger O (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74:3–14. https://doi.org/10.1159/000101046CrossRef

64.

Cuesta AM, Sánchez-Martín D, Sanz L et al (2009) In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One 4:e5381. https://doi.org/10.1371/journal.pone.0005381CrossRefPubMedCentral

65.

Oliveira SS, Aires da Silva F, Lourenco S et al (2012) Assessing combinatorial strategies to multimerize libraries of single-domain antibodies. Biotechnol Appl Biochem 59:193–204. https://doi.org/10.1002/bab.1011CrossRef

66.

Thie H, Binius S, Schirrmann T et al (2009) Multimerization domains for antibody phage display and antibody production. N Biotechnol 26:314–321. https://doi.org/10.1016/j.nbt.2009.07.005CrossRef

67.

Lambert JM (2013) Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76:248–262. https://doi.org/10.1111/bcp.12044CrossRef

68.

Casi G, Neri D (2012) Antibody–drug conjugates: basic concepts, examples and future perspectives. J Control Release 161:422–428. https://doi.org/10.1016/J.JCONREL.2012.01.026CrossRef

69.

Chudasama V, Maruani A, Caddick S (2016) Recent advances in the construction of antibody–drug conjugates. Nat Chem 8:114–119. https://doi.org/10.1038/nchem.2415CrossRef

70.

Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T et al (2019) Antibody–drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol 234:5628–5642. https://doi.org/10.1002/jcp.27419CrossRef

71.

Arruebo M, Valladares M, González-Fernández Á (2009) Antibody-conjugated nanoparticles for biomedical applications. J Nanomater 2009:1–24. https://doi.org/10.1155/2009/439389CrossRef

72.

Bertrand N, Wu J, Xu X et al (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. https://doi.org/10.1016/J.ADDR.2013.11.009CrossRef

73.

Krishnamurthy A, Jimeno A (2017) Bispecific antibodies for cancer therapy: a review. Pharmacol Ther. https://doi.org/10.1016/j.pharmthera.2017.12.002

74.

Nagorsen D, Bargou R, Rüttinger D et al (2009) Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 50:886–891. https://doi.org/10.1080/10428190902943077CrossRef

75.

Baeuerle PA, Kufer P, Bargou R (2009) BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11:22–30

76.

Gross G, Eshhar Z (2016) Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol 56:59–83. https://doi.org/10.1146/annurev-pharmtox-010814-124844CrossRef

77.

Pule M, Finney H, Lawson A (2003) Artificial T-cell receptor. Cytotherapy 5:211–226. https://doi.org/10.1080/14653240310001488CrossRef

78.

American Association for Cancer (2017) First-ever CAR T-cell therapy approved in U.S. Cancer Discov 7. https://doi.org/10.1158/2159-8290.CD-NB2017-126

79.

Grand View Research (2016) Monoclonal antibodies (mAbs) market size worth $138.6 billion by 2024

80.

Elgundi Z, Reslan M, Cruz E et al (2016) The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. https://doi.org/10.1016/j.addr.2016.11.004

81.

Bunnak P, Allmendinger R, Ramasamy SV et al (2016) Life-cycle and cost of goods assessment of fed-batch and perfusion-based manufacturing processes for mAbs. Biotechnol Prog 32:1324–1335. https://doi.org/10.1002/btpr.2323CrossRefPubMedCentral

82.

Nieri P, Donadio D, Rossi S et al (2009) Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 16:753–779. https://doi.org/10.2174/092986709787458380CrossRef

83.

Orlandi R, Gussow DH, Jones PT, Winter G (1989) Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci 86:3833–3837. https://doi.org/10.1073/pnas.86.10.3833CrossRef

84.

Gussow D, Ward ES, Griffiths AD et al (1989) Generating binding activities from Escherichia coli by expression of a repertoire of immunoglobulin variable domains. Cold Spring Harb Symp Quant Biol 54:265–272. https://doi.org/10.1101/SQB.1989.054.01.033CrossRef

85.

McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554. https://doi.org/10.1038/348552a0CrossRef

86.

Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105–1116. https://doi.org/10.1038/nbt1126CrossRef

87.

Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K (2011) High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 16:3675–3700. https://doi.org/10.3390/molecules16053675CrossRefPubMedCentral

88.

Adams JJ, Nelson B, Sidhu SS (2014) Recombinant genetic libraries and human monoclonal antibodies. Methods Mol Biol 1060:149–170. https://doi.org/10.1007/978-1-62703-586-6_9CrossRef

89.

Aires da Silva F, Corte-Real S, Goncalves J (2008) Recombinant antibodies as therapeutic agents. BioDrugs 22:301–314. https://doi.org/10.2165/00063030-200822050-00003CrossRef

90.

Hust M, Frenzel A, Meyer T et al (2012) Construction of human naive antibody gene libraries. In: Gene function analysis, methods in molecular biology. Humana Press, Totowa, pp 85–107

91.

Vaughan TJ, Williams AJ, Pritchard K et al (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14:309–314. https://doi.org/10.1038/nbt0396-309CrossRef

92.

Soon Lim T, Khim Chan S (2016) Immune antibody libraries: manipulating the diverse immune repertoire for antibody discovery. Curr Pharm Des 22:6480–6489. https://doi.org/10.2174/1381612822666160923111924CrossRef

93.

Posner B, Lee I, Itoh T et al (1993) A revised strategy for cloning antibody gene fragments in bacteria. Gene 128:111–117. https://doi.org/10.1016/0378-1119(93)90161-UCrossRef

94.

Nuttall SD (2012) Overview and discovery of IgNARs and generation of VNARs. Methods Mol Biol 911:27–36. https://doi.org/10.1007/978-1-61779-968-6_3CrossRef

95.

Wesolowski J, Alzogaray V, Reyelt J et al (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198:157–174. https://doi.org/10.1007/s00430-009-0116-7CrossRefPubMedCentral

96.

Adams JJ, Sidhu SS (2014) Synthetic antibody technologies. Curr Opin Struct Biol 24:1–9. https://doi.org/10.1016/j.sbi.2013.11.003CrossRef

97.

Hoogenboom HR, Winter G (1992) By-passing immunisation. J Mol Biol 227:381–388. https://doi.org/10.1016/0022-2836(92)90894-PCrossRef

98.

Yang HY, Kang KJ, Chung JE, Shim H (2009) Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol Cells 27:225–235. https://doi.org/10.1007/s10059-009-0028-9CrossRef

99.

Silacci M, Brack S, Schirru G et al (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5:2340–2350. https://doi.org/10.1002/pmic.200401273CrossRef

100.

Cunha-santos C, Figueira TN, Borrego P, Oliveira SS (2016) Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS 30(11):1691–1701CrossRef

101.

Tiller T, Schuster I, Deppe D et al (2013) A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 5:445–470. https://doi.org/10.4161/mabs.24218CrossRefPubMedCentral

102.

Prassler J, Thiel S, Pracht C et al (2011) HuCAL PLATINUM, a synthetic fab library optimized for sequence diversity and superior performance in mammalian expression systems. J Mol Biol 413:261–278. https://doi.org/10.1016/j.jmb.2011.08.012CrossRef

103.

Shim H (2015) Synthetic approach to the generation of antibody diversity. BMB Rep 48:489–494. https://doi.org/10.5483/BMBRep.2015.48.9.120CrossRefPubMedCentral

104.

Miersch S, Sidhu SS (2012) Synthetic antibodies: concepts, potential and practical considerations. Methods 57:486–498. https://doi.org/10.1016/j.ymeth.2012.06.012CrossRef

105.

Hoet RM, Cohen EH, Kent RB et al (2005) Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol 23:344–348. https://doi.org/10.1038/nbt1067CrossRef

106.

Soderlind E, Strandberg L, Jirholt P et al (2000) Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 18:852–856. https://doi.org/10.1038/78458CrossRef

107.

Hartwell L, Hood L, Goldberg M et al (2008) Genetics: from genes to genomes, 4th edn. McGraw Hill, New York

108.

Bradbury ARM, Sidhu S, Dubel S, McCafferty J (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29:245–254. https://doi.org/10.1038/nbt.1791CrossRefPubMedCentral

109.

Barbas CF, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci 88:7978–7982. https://doi.org/10.1073/pnas.88.18.7978CrossRef

110.

Smith G (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317. https://doi.org/10.1126/science.4001944CrossRef

111.

Huang JX, Bishop-Hurley SL, Cooper MA (2012) Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother 56:4569–4582. https://doi.org/10.1128/AAC.00567-12CrossRefPubMedCentral

112.

Barbas CF (1995) Synthetic human antibodies. Nat Med 1:837–839. https://doi.org/10.1038/340091a0CrossRef

113.

Bain B, Brazil M (2003) Adalimumab. Nat Rev Drug Discov 2:693–694. https://doi.org/10.1038/nrd1182CrossRef

114.

Vendel MC, Favis M, Snyder WB et al (2012) Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties. Arch Biochem Biophys 526:188–193. https://doi.org/10.1016/j.abb.2011.12.018CrossRef

115.

Lipovsek D, Plückthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290:51–67. https://doi.org/10.1016/j.jim.2004.04.008CrossRef

116.

Ullman CG, Frigotto L, Cooley RN (2011) In vitro methods for peptide display and their applications. Brief Funct Genomics 10:125–134. https://doi.org/10.1093/bfgp/elr010CrossRef

117.

Doerner A, Rhiel L, Zielonka S, Kolmar H (2014) Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett 588:278–287. https://doi.org/10.1016/j.febslet.2013.11.025CrossRef

118.

Black CB, Duensing TD, Trinkle LS, Dunlay RT (2011) Cell-based screening using high-throughput flow cytometry. Assay Drug Dev Technol 9:13–20. https://doi.org/10.1089/adt.2010.0308CrossRefPubMedCentral

119.

Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553–557. https://doi.org/10.1038/nbt0697-553CrossRef

120.

Cherf GM, Cochran JR (2015) Applications of yeast surface display for protein engineering. Yeast Surf Disp Methods Protoc Appl:155–175. https://doi.org/10.1007/978-1-4939-2748-7_8

121.

Koide S, Koide A, Lipovšek D (2012) Target-binding proteins based on the 10th human fibronectin type III domain (10 Fn3). Methods Enzymol 503:135–156. https://doi.org/10.1016/B978-0-12-396962-0.00006-9CrossRef

122.

Boder ET, Raeeszadeh-Sarmazdeh M, Price JV (2012) Engineering antibodies by yeast display. Arch Biochem Biophys 526:99–106. https://doi.org/10.1016/j.abb.2012.03.009CrossRef

123.

Zhou C, Jacobsen FW, Cai L et al (2010) Development of a novel mammalian cell surface antibody display platform. MAbs 2:508–518. https://doi.org/10.4161/mabs.2.5.12970CrossRefPubMedCentral

124.

Mitchell Ho IP (2009) Mammalian cell display for antibody. Engineering 525:1–15. https://doi.org/10.1007/978-1-59745-554-1CrossRef

125.

Zhang H, Wilson IA, Lerner RA (2012) Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries. Proc Natl Acad Sci U S A 109:15728–15733. https://doi.org/10.1073/pnas.1214275109CrossRefPubMedCentral

126.

Beerli RR, Bauer M, Buser RB et al (2008) Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 105:14336–14341. https://doi.org/10.1073/pnas.0805942105CrossRefPubMedCentral

127.

Walker JM (2012) Antibody engineering methods and protocols, 2nd edn. Humana Press, Totowa

128.

Lu WC, Ellington AD (2013) In vitro selection of proteins via emulsion compartments. Methods 60:75–80. https://doi.org/10.1016/j.ymeth.2012.03.008CrossRef

129.

Tawfik DS, Griffiths AD (1998) Man-made cell-like compartments for molecular evolution. Nat Biotechnol 16:652–656. https://doi.org/10.1038/nbt0798-652CrossRef

130.

Kennedy PJ, Oliveira C, Granja PL, Sarmento B (2017) Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol 0:1–15. https://doi.org/10.1080/07388551.2017.1357002CrossRef

131.

Lutz S (2011) Beyond directed evolution – semi-rational protein engineering and design. Curr Opin Biotechnol 21:734–743. https://doi.org/10.1016/j.copbio.2010.08.011.BeyondCrossRef

132.

Boder ET, Midelfort KS, Wittrup KD (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci 97:10701–10705. https://doi.org/10.1073/pnas.170297297CrossRef

133.

Packer MS, Liu DR (2015) Methods for the directed evolution of proteins. Nat Rev Genet 16:379–394. https://doi.org/10.1038/nrg3927CrossRefPubMedCentral

134.

Thie H, Voedisch B, Dübel S et al (2009) Affinity maturation by phage display. Methods Mol Biol 525:309–322. https://doi.org/10.1007/978-1-59745-554-1_16CrossRef

135.

Cadwell RC, Joyce GF (1994) Mutagenic PCR. PCR Methods Appl 3:S136–S140CrossRef

136.

Coia G, Hudson PJ, Irving RA (2001) Protein affinity maturation in vivo using E. coli mutator cells. J Immunol Methods 251:187–193. https://doi.org/10.1016/S0022-1759(01)00300-3CrossRef

137.

Marks JD, Griffiths AD, Malmqvist M et al (1992) By-passing immunization: building high affinity human antibodies by chain shuffling. Nat Biotechnol 10:779–783. https://doi.org/10.1038/nbt0792-779CrossRef

138.

Yang W-P, Green K, Pinz-Sweeney S et al (1995) CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392–403. https://doi.org/10.1006/jmbi.1995.0626CrossRef

139.

Wang HH, Isaacs FJ, Carr PA et al (2009) Programming cells by multiplex genome engineering and accelerated evolution. Nature 460:894–898. https://doi.org/10.1038/nature08187CrossRefPubMedCentral

140.

Hartl DL (2015) What can we learn from fitness landscapes? Curr Opin Microbiol:213–223. https://doi.org/10.1007/978-1-62703-673-3

141.

Leemhuis H, Stein V, Griffiths AD, Hollfelder F (2005) New genotype-phenotype linkages for directed evolution of functional proteins. Curr Opin Struct Biol 15:472–478. https://doi.org/10.1016/j.sbi.2005.07.006CrossRef

142.

Arnold F, Georgiou G (2003) Directed evolution library creation. Humana Press, TotowaCrossRef

143.

Smith SA, Crowe JE (2015) Use of human hybridoma technology to isolate human monoclonal antibodies. Microbiol Spectr 3:1–12. https://doi.org/10.1128/microbiolspec.AIDCrossRef

144.

Chan CEZ, Lim APC, MacAry PA, Hanson BJ (2014) The role of phage display in therapeutic antibody discovery. Int Immunol 26:649–657. https://doi.org/10.1093/intimm/dxu082CrossRefPubMedCentral

145.

Ho M, Pastan I (2009) Display and selection of scFv antibodies on HEK-293T cells. In: Antibody phage display: methods and protocols, 2nd edn. Humana Press, Totowa, pp 99–113

Titel: Therapeutic Antibody Engineering and Selection Strategies
verfasst von: Joana Ministro
Ana Margarida Manuel
Joao Goncalves
Verlag: Springer International Publishing
Buch: Current Applications of Pharmaceutical Biotechnology
Print ISBN: 978-3-030-40463-5

Electronic ISBN: 978-3-030-40464-2

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/10_2019_116

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht